| Issue Date | Title | Author(s) |
| 2019 | All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china | Wei, Lai; Xu, Xiaoyuan; Guan, Yujuan; Zheng, Sujun; Sheng, Ji-Fang; Yang, Xingxiang; Ma, Yuanji; Huang, Yan; Kang, Yi; Wen, Xiaofeng; Li, Jun; Tan, Youwen; He, Qing; Xie, Qing; Wang, Maorong; An, Ping; Gong, Guozhong; Liu, Huimin; Ning, Qin; Hua, Rui; Ning, Bo; Xie, Wen; Zhang, Jiming; Huang, Wenxiang; Yang, Yongfeng; Lin, Minghua; Zhao, Yingren; Yu, Yanhong; Jia, Ji-Dong; Yang, Dongliang; Chen, Liang; Ye, Yinong; Nan, Yuemin; Gong, Zuojong; Zhang, Quan; Hu, Peng; Wang, Fu-Sheng; Li, Yongguo; Li, Dongliang; Jia, Zhansheng; Hou, Jinlin; Chen, Chengwei; Wu, Jinzi |
| Jul-2020 | Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis | Rao, Huiying; Yang, Xingxiang; Tan, Youwen; Ning, Qin; Yang, Daokun; Wang, Jiefei; Yang, Yongfeng; Zheng, Sujun; Yang, Dongliang; Hou, Jinlin; Xie, Qing; Zhao, Caiyan; Zhang, Lunli; Mao, Xiaorong; Sun, Tong; Bai, Lang; Zhang, Fuchun; Jin, Jinglan; Zhao, Yingren; Wang, Maorong; Xie, Wen; Ma, Yingjie; Quan, Jun; Yan, Xuebing; An, Ping; Lin, Feng; Jia, Jidong; Hu, Xiaoxuan; Gong, Zuojiong; Wu, Jie; Chen, Yongping; Jia, Zhansheng; Lin, Minghua; Wang, Guiqiang; Zhu, Yueyong; Zhang, Yingjun; Xie, Hongming; Luo, Lin; Ren, Qingyun; Huang, Rui; Wei, Lai |
| 2018 | Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China | Wei, Lai; Xu, Xiaoyun; Guan, Yujuan; Zheng, Sujun; Sheng, Jifang; Yang, Xingxiang; Ma, Yuanji; Huang, Yan; Kang, Yi; Wen, Xiaofeng; Li, Jun; Tan, Youwen; He, Qing; Xie, Qing; Wang, Maorong; An, Ping; Gong, Guozhong; Liu, Huimin; Ning, Qin; Hua, Rui; Ning, Bo; Xie, Wen; Zhang, Jiming; Huang, Wenxiang; Yang, Yongfeng; Lin, Minghua; Zhao, Yingren; Yu, Yanhong; Jia, Jidong; Yang, Dongliang; Chen, Liang; Ye, Yinong; Nan, Yuemin; Gong, Zuojiong; Zhang, Quan; Hu, Peng; Wang, FuSheng; Li, Yongguo; Li, Dongliang; Jia, Zhansheng; Hou, Jinlin; Chen, Chengwei |
| 2018 | Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China | Wei, Lai; Xu, Xiaoyun; Guan, Yujuan; Zheng, Sujun; Sheng, Jifang; Yang, Xingxiang; Ma, Yuanji; Huang, Yan; Kang, Yi; Wen, Xiaofeng; Li, Jun; Tan, Youwen; He, Qing; Xie, Qing; Wang, Maorong; An, Ping; Gong, Guozhong; Liu, Huimin; Ning, Qin; Hua, Rui; Ning, Bo; Xie, Wen; Zhang, Jiming; Huang, Wenxiang; Yang, Yongfeng; Lin, Minghua; Zhao, Yingren; Yu, Yanhong; Jia, Jidong; Yang, Dongliang; Chen, Liang; Ye, Yinong; Nan, Yuemin; Gong, Zuojiong; Zhang, Quan; Hu, Peng; Wang, FuSheng; Li, Yongguo; Li, Dongliang; Jia, Zhansheng; Hou, Jinlin; Chen, Chengwei |
| 2019 | Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naive Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China | Xu, Xiaoyuan; Feng, Bo; Guan, Yujuan; Zheng, Sujun; Sheng, Jifang; Yang, Xingxiang; Ma, Yuanji; Huang, Yan; Kang, Yi; Wen, Xiaofeng; Li, Jun; Tan, Youwen; He, Qing; Xie, Qing; Wang, Maorong; Anl, Ping; Gong, Guozhong; Liu, Huimin; Nine, Qin; Hua, Rui; Ning, Bo; Xie, Wen; Zhang, Jiming; Huang, Wenxiang; Yang, Yongfeng; Lin, Minghua; Zhao, Yingren; Yu, Yanhong; Jia, Jidong; Yang, Dongliang; Chen, Liang; Ye, Yinong; Nan, Yuemin; Gong, Zuojiong; Zhang, Quan; Hu, Peng; Wang, Fusheng; Li, Yongguo; Li, Dongliang; Jia, Zhansheng; Hou, Jinlin; Chen, Chengwei; Wu, Jinzi J.; Wei, Lai |
| 2019 | THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL | Wei, Lai; Xu, Xiaoyuan; Zheng, Sujun; Guan, Yujuan; Sheng, Jifang; Yang, Xingxiang; Ma, Yuanji; Huang, Yan; Kang, Yi; Wen, Xiaofeng; Li, Jun; Tan, Youwen; He, Qing; Xie, Qing; Wang, Maorong; An, Ping; Gong, Guozhong; Liu, Huimin; Ning, Qing; Hua, Rui; Ning, Bo; Xie, Wen; Zhang, Jiming; Huang, Wenxiang; Yang, Yongfeng; Lin, Minghua; Zhao, Yingren; Yu, Yanhong; Jia, Jidong; Yang, Dongliang, Sr.; Chen, Liang; Ye, Yinong, Sr.; Nan, Yuemin; Gong, Zuojiong; Zhang, Quan; Hu, Peng; Wang, FuSheng; Li, Yongguo; Li, Dongliang; Jia, Zhansheng; Hou, Jinlin; Chen, Chengwei; Wu, Jinzi |
| Oct-2021 | FUNCTIONAL CURE BASED ON PEGYLATED INTERFERON alpha IN LONG-TERM NUCLEOSIDE ANALOG SUPPRESSED HBEAG NEGATIVE CHRONIC HEPATITIS B: A MULTICENTER REAL-WORLD STUDY (EVEREST PROJECT IN CHINA), A SEQUENTIAL REPORT - THE PREDICTORS FOR HBsAg LOSS | Wu, Zeqian; Xie, Dongying; Fu, Lei; Zhang, Wenhua; Wei, Jia; Shang, Jia; Li, Guojun; Guo, Ying; Yang, Jiahong; Guan, Yujuan; Li, Jiabin; Chang, Jiabao; Huang, Guangyu; Peng, Yanzhong; Lin, Minghua; Zeng, Yilan; Li, Jia; Jiang, Jiaji; Jiang, Yongfang; Gu, Ye; Geng, Jiawei; Gao, Zhiliang |
| Jul-2022 | Functional cure based on pegylated interferon alpha therapy in nucleoside analog-suppressed HBeAg negative chronic hepatitis B: a multicenter real-world study (Everest Project in China)-3.5 years data update | Xie, Chan; Xie, Dongying; Fu, Lei; Zhang, Wen-hua; Wei, Jia; Li, Guojun; Yang, Jiahong; Chen, Xinyue; Li, Jia-bin; Shang, Jia; Guan, Yu-juan; Jiang, Yongfang; Guo, Ying; Zeng, Yi-lan; Chang, Jiabao; Peng, Yanzhong; Lin, Minghua; Huang, Guangyu; Li, Jia; Gu, Shengwang; Geng, Jia-wei; Gao, Zhiliang |
